Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083787 | 0.86 | DCUN1D1 (0.43) | ACHEDCUN1D1ALOX5APFEN1IDO1 | |
| SCHEMBL21075531 | 0.86 | ALOX5AP (0.56) | DCUN1D1ALOX5APFEN1CNR2IDO1 | |
| SCHEMBL20697685 | 0.85 | ALOX5AP (0.44) | DCUN1D1ALOX5APFEN1IDO1DRD2 | |
| SCHEMBL17428664 | 0.84 | DCUN1D1 (0.46) | ACHEKMT2ADCUN1D1CNR2HRH3 | |
| SCHEMBL23179558 | 0.82 | ACHE (0.51) | ACHEKMT2AHRH3DRD2DRD4 | |
| SCHEMBL18908954 | 0.78 | SCN9A (0.43) | ACHEKMT2ADCUN1D1CNR2HRH3 | |
| SCHEMBL14242820 | 0.77 | HRH3 (0.67) | ACHEHRH3ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28813879 | 0.76 | HRH3 (0.65) | ACHEHRH3ALDH1A1 | |
| SCHEMBL14708571 | 0.75 | KDM4E (0.68) | ACHEKMT2ACNR2DRD4ALDH1A1 | |
| SCHEMBL12013928 | 0.75 | ACHE (0.68) | ACHEKMT2AHRH3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ACHE 1652/4885KMT2A 1836/4885DCUN1D1 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.